AIDSWEEKLY Plus; Monday, December 24 & 31, 2001
Michael Greer, Senior Medical Writer
NewsRx -- Cytokines and growth factors can improve the effectiveness of DNA HIV vaccines although they have little effect on the type of induced immune responses, researchers in the United States say.
"The effects of genetic adjuvants on humoral and cell-mediated immunity to two human immunodeficiency virus antigens, Env and Nef, have been examined in mice," according to Anne C. Moore and colleagues at the National Institutes of Health's Vaccine Research Center in Bethesda, Maryland.
Adjuvants could have a positive impact on vaccine efficacy but only in degree and not in kind, Moore and coworkers found.
They compared murine immune responses with vaccines based on genes coding for the HIV proteins Env and Nef. While Nef-based vaccines induced strong antibody responses aided by HIV specific gamma interferon (IFN-(gamma)), Env-based vaccines produced potent cytotoxic T-lymphocyte (CTL) activity but weak humoral responses, they said.
A number of genes coding for cytokines and hematopoietic growth factors were studied as possible adjuvants for Env and Nef vaccines. Granulocyte-macrophage colony-stimulating factor increased CTL activity and IFN-(gamma) output in response to Env, study data showed, while interleukin-12 with Flt3 ligand enhanced immunoglobulin G antibody responses and IFN-(gamma) production after treatment with Nef-based vaccines.
However, these adjuvants did little to improve CTL responses to Nef or humoral responses to Env (Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice, Journal of Virology, January 2002;76(1):243-250).
"These findings suggest that intrinsic properties of the antigen determine the character of immune reactivity for this method of immunization," Moore and coauthors concluded, "and that specific combination of innate and adaptive immune cytokine genes can increase the magnitude of the response to DNA vaccines."
The corresponding author for this report is Gary J. Nabel, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Dr., Bethesda, MD 20892, USA. E-mail: gnabel@nih.gov.
A search at www.NewsRx.net using the term "AIDS and HIV vaccine" yielded 121 articles in 17 specialized reports.
Key points reported in this study include:
This article was prepared by AIDS Weekly editors from staff and other reports.
011224
AW011211
Copyright © 2001 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1990,2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.